Christopher James Bungard,Antonella Converso,Pablo De Leon,Barbara Hanney,Timothy John Hartingh,Jesse Josef Manikowski,Peter J. Manley,Robert Meissner,Zhaoyang Meng,James J. Perkins,Michael T. Rudd,Yo
申请号：
US15047213
公开号：
US09663506B2
申请日:
2016.02.18
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I)wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
